Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Let's see if Bausch Health Companies Inc. (BHC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Should Value Investors Pick Bausch Health (BHC) Stock Now?

Cisco Systems

We will be buying 700 shares of Bausch Health and 100 shares of Cisco Systems.

Cramer's Investing Club: We're adding to two portfolio stocks in this volatile market

LAVAL, QC, Jan. 27, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced its previously announced offering of $1.0 billion aggregate principal amount of 6.125% senior secured notes due 2027 (the "Notes"). The Notes will be sold to investors at a price of 100% of the principal amount thereof.

Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes

LAVAL, QC, Jan. 27, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $1.0 billion aggregate principal amount of new senior secured notes due 2027 (the "Notes"). As previously announced, the Company is also seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing").

Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes

In the latest trading session, Bausch Health (BHC) closed at $25.06, marking a +0.56% move from the previous day.

Bausch Health (BHC) Gains As Market Dips: What You Should Know

Aurinia Pharmaceuticals

Clovis Oncology

Myovant Sciences

Cassava Sciences Inc

SPDR S&P Biotech ETF

Biotechs have been one of the worst performers for 2021 as the pandemic has wrought havoc in the sector. 2022 will likely entail a rotation out of high valuation sectors like technology into more depressed sectors like healthcare.

6 Top Biotech Ideas For 2022

LAVAL, QC, Jan. 20, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") has announced that Dr. Yehia Hashad will join Bausch + Lomb Corporation ("Bausch + Lomb") as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective Jan. 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11 years he held various roles, including leading Allergan's global clinical development program for its eye care portfolio.

Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer

LAVAL, QB, Jan. 18, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the "New Term B Loans") and a $975 million revolving credit facility.

Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation

Bausch Health Companies Inc.'s ( BHC , Financial) plans to split into three public companies is pretty much a done deal, CEO Joseph Papa said at last week's J.P. Morgan Healthcare Conference.

Investors Will Have Opportunity to Invest in Bausch Spinoffs

Bausch + Lomb has filed to raise $100 million in an IPO, although the final figure may be significantly higher. Bausch + Lomb develops and sells eyecare products to consumers, pharmaceutical firms and surgical markets worldwide.

Bausch + Lomb Begins U.S. IPO Process

Bausch Health Companies ( BHC , Financial) ( TSX:BHC , Financial), which is dual listed in the U.S. and Canada, is planning on splitting into three companies this year - Bausch+Lomb, Solta Medical and Bausch Pharma. The main event is the Bausch+Lomb spinoff, in my view; it seems like the split is aimed at making Bausch+Lomb into an investment-worthy company.

Bausch Spins Forward to Unlock Value

Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.

Bausch (BHC) Eye Care Business Files for IPO in the US & Canada

Bausch Health Companies Inc (NYSE:BHC) just said that its eye-care products unit Bausch + Lomb filed to go public on Thursday on both U.S. and Canadian exchanges via an initial public offering (IPO).

Bausch Health Spinoff Sends Stock Higher

Bausch & Lomb Corp filed S-1 for its initial public offering, nearly 1.5 years after its parent company, Bausch Health Companies Inc (NYSE: BHC) said it would spin off the eye-care company. The company said it plans to raise $100 million in its IPO.

Bausch Health's Eye-Care Spin-Off Entity Files For $100M IPO

Bausch & Lomb Corp. has filed for an initial public offering, according to a filing late Thursday. The Bausch Health Cos.

Bausch & Lomb files for IPO, parent Bausch Health to remain majority owner

LAVAL, QC and VAUGHAN, ON, Jan. 13, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") announced today that, in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb Corporation ("Bausch + Lomb"), has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") and a preliminary base post-receipt pricing procedure ("PREP") prospectus with the securities regulatory authorities in each of the provinces and territories of Canada (other than Quebec) ("Canadian Regulators") relating to a proposed initial public offering ("IPO") of Bausch + Lomb's common shares concurrently in the United States and Canada. All of the shares being offered will be sold by a wholly owned subsidiary of Bausch Health.

Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering

Bausch Health (BHC) closed the most recent trading day at $27.34, moving -1.51% from the previous trading session.

Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know

Bausch Health Companies, Inc. (BHC) CEO Joe Papa at 40th Annual J.P. Morgan Healthcare Conference (Transcript)

While we do not violate our overall cost basis lightly, we do believe the weakness thus far in 2022 is presenting an opportunity that we want to take advantage.

We're bulking up on this health-care name before it gets away from us

LAVAL, Quebec, Jan. 11, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") will provide a progress update on its business and strategic initiatives in a published presentation designed to complement remarks that will be provided by management at 9 a.m. ET tomorrow, Jan. 12, 2022, during a fireside chat at the 40th Annual J.P.

Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference

Bausch has reduced net debt by some $5 billion since the worst of the turmoil in 2017. This makes a dent in leverage, certainly as the underlying business has stabilized.

Bausch Health: Getting Healthier, Gradually

Bausch Health Companies Inc. ( BHC , Financial) has traded in a low range for years, but that could soon change. The company is making progress on its research and recently announced a collaboration with the Glaucoma Research Foundation to raise awareness of hyperemia and how it may have an impact on the lives of patients with glaucoma.

Bausch Health Companies Is Doing Good and Doing Well

Chevron

Honeywell

Eli Lilly

Appearing on CNBC's "Halftime Report," Jim Cramer explained why Chevron, Eli Lilly, Honeywell and Bausch Health are some of his favorite stocks for the new year.

Here are 4 of Jim Cramer's top stock picks for 2022

Our reassessment comes ahead of the company's presentation at the annual J.P. Morgan Healthcare Conference next week.

We're increasing our price target on a club health stock

LAVAL, QC, Jan. 5, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 40th Annual J.P.

News for Bausch Health Companies Inc Stock (BHC)